Dexcom Inc
DXCM70.464USD
-0.916-1.28%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
27.53BMarktkapitalisierung
47.78KGV TTM
mehr Informationen über Dexcom Inc Unternehmen
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Unternehmensinformationen
Unternehmens-codeDXCM
Name des UnternehmensDexcom Inc
IPO-datumApr 14, 2005
Gegründet am1999
CEOMr. Kevin R. Sayer
Anzahl der mitarbeiter10300
WertpapierartOrdinary Share
GeschäftsjahresendeApr 14
Addresse6340 Sequence Dr
StadtSAN DIEGO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl92121
Telefon18582000200
Websitehttps://www.dexcom.com/
Unternehmens-codeDXCM
IPO-datumApr 14, 2005
Gegründet am1999
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Eric J. Topol, M.D.
Dr. Eric J. Topol, M.D.
Independent Director
Independent Director
380.55K
+0.77%
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
276.26K
+6.52%
Mr. Kevin R. Sayer
Mr. Kevin R. Sayer
Chairperson of the Board, President, Chief Executive Officer
Chairperson of the Board, President, Chief Executive Officer
233.94K
+11.70%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Lead Independent Director
Lead Independent Director
59.37K
-4.34%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
58.63K
+5.18%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
41.94K
+7.44%
Mr. Jereme M. Sylvain
Mr. Jereme M. Sylvain
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
40.15K
+34.41%
Mr. Nicholas (Nick) Augustinos
Mr. Nicholas (Nick) Augustinos
Independent Director
Independent Director
39.70K
+8.30%
Ms. Bridgette P. Heller
Ms. Bridgette P. Heller
Independent Director
Independent Director
23.00K
-1.51%
Mr. Kyle Malady
Mr. Kyle Malady
Independent Director
Independent Director
18.14K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Eric J. Topol, M.D.
Dr. Eric J. Topol, M.D.
Independent Director
Independent Director
380.55K
+0.77%
Mr. Jacob Steven (Jake) Leach
Mr. Jacob Steven (Jake) Leach
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
276.26K
+6.52%
Mr. Kevin R. Sayer
Mr. Kevin R. Sayer
Chairperson of the Board, President, Chief Executive Officer
Chairperson of the Board, President, Chief Executive Officer
233.94K
+11.70%
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Lead Independent Director
Lead Independent Director
59.37K
-4.34%
Mr. Steven R. (Steve) Altman
Mr. Steven R. (Steve) Altman
Independent Director
Independent Director
58.63K
+5.18%
Mr. Richard Alexander Collins
Mr. Richard Alexander Collins
Independent Director
Independent Director
41.94K
+7.44%
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Distributor
3.43B
85.05%
Direct
602.90M
14.95%
Nach RegionUSD
Name
Umsatz
Anteil
United States
2.89B
71.65%
Outside of United states
1.14B
28.35%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Distributor
3.43B
85.05%
Direct
602.90M
14.95%
Aktionäre
Update-Zeit: Fri, Feb 21
Update-Zeit: Fri, Feb 21
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
11.82%
BlackRock Institutional Trust Company, N.A.
6.17%
State Street Global Advisors (US)
4.26%
Baillie Gifford & Co.
3.73%
Capital Research Global Investors
3.67%
Other
70.36%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
11.82%
BlackRock Institutional Trust Company, N.A.
6.17%
State Street Global Advisors (US)
4.26%
Baillie Gifford & Co.
3.73%
Capital Research Global Investors
3.67%
Other
70.36%
Art
Aktionäre
Anteil
Investment Advisor
44.84%
Investment Advisor/Hedge Fund
35.69%
Hedge Fund
6.59%
Research Firm
3.56%
Pension Fund
2.27%
Bank and Trust
1.61%
Sovereign Wealth Fund
1.44%
Individual Investor
0.38%
Venture Capital
0.34%
Other
3.27%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
2198
383.01M
97.68%
-27.58M
2024Q4
2220
380.88M
97.47%
-26.96M
2024Q3
2145
382.31M
97.83%
-30.58M
2024Q2
2115
397.02M
99.11%
-4.31M
2024Q1
2093
389.18M
98.33%
-19.87M
2023Q4
2081
398.01M
103.26%
+83.33K
2023Q3
1994
389.89M
100.89%
-11.88M
2023Q2
1952
389.17M
100.78%
-12.73M
2023Q1
1908
390.83M
100.84%
-11.09M
2022Q4
1889
389.49M
100.81%
-14.66M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
46.36M
11.82%
-900.98K
-1.91%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
24.18M
6.17%
+3.21K
+0.01%
Dec 31, 2024
State Street Global Advisors (US)
16.69M
4.26%
+19.76K
+0.12%
Dec 31, 2024
Baillie Gifford & Co.
14.61M
3.73%
-404.87K
-2.70%
Dec 31, 2024
Capital Research Global Investors
14.37M
3.67%
-3.58M
-19.93%
Dec 31, 2024
Sands Capital Management, LLC
11.11M
2.83%
+790.30K
+7.66%
Dec 31, 2024
Geode Capital Management, L.L.C.
9.99M
2.55%
+56.09K
+0.56%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
8.08M
2.06%
+108.41K
+1.36%
Feb 28, 2025
Nuveen LLC
7.82M
2%
+61.83K
+0.80%
Dec 31, 2024
Jennison Associates LLC
7.64M
1.95%
+710.86K
+10.25%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
First Trust Nasdaq Lux Digi Health Solutions ETF
9.74%
Simplify Market Neutral Equity Long/Short ETF
9%
Langar Global HealthTech ETF
6.72%
Global X Internet of Things ETF
4.93%
Touchstone Sands Capital US Select Growth ETF
4.63%
Harbor Health Care ETF
4.29%
Motley Fool Mid-Cap Growth ETF
3.88%
Fidelity Digital Health ETF
3.8%
Motley Fool Global Opportunities ETF
3.63%
Global X Telemedicine & Digital Health ETF
3.55%
Mehr Anzeigen
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil9.74%
Simplify Market Neutral Equity Long/Short ETF
Anteil9%
Langar Global HealthTech ETF
Anteil6.72%
Global X Internet of Things ETF
Anteil4.93%
Touchstone Sands Capital US Select Growth ETF
Anteil4.63%
Harbor Health Care ETF
Anteil4.29%
Motley Fool Mid-Cap Growth ETF
Anteil3.88%
Fidelity Digital Health ETF
Anteil3.8%
Motley Fool Global Opportunities ETF
Anteil3.63%
Global X Telemedicine & Digital Health ETF
Anteil3.55%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 28, 2022
Split
1>4
Datum
Art
Verhältnis
Mar 28, 2022
Split
1>4